Search Results
Nov 03, 2025, 08:08 ET Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
patients with HCC and severe renal impairment. LENVIMA has not been studied in patients with end-stage renal disease. No dose adjustment is recommended for patients with HCC and mild hepatic impairment (Child-Pugh A). There is no recommended dose for patients with HCC with moderate
More news about: Eisai Inc.
Oct 28, 2025, 08:34 ET RAAPID Earns 2025 Great Place To Work Certification™ for Second Consecutive Year
payers, providers, and supporting organizations. The company's HITRUST-certified platform uses neuro-symbolic AI to identify chronic conditions, determine HCC codes, calculate risk scores, and analyze population health trends. Following a Series A investment from M12 (Microsoft's venture fund), RAAPID serves
More news about: RAAPID INC
Oct 27, 2025, 09:12 ET John Legend Surprises Guests at the Fetch Pet Gala After Party Presented by Kismet
Cozen O'Connor, GlobalLogic, Goldman Sachs Group, Inc., Icon Media Direct, JPMorganChase, Pet Insurance Quotes LLC, Raymond James, Sapiens, Tokio Marine HCC, Aon, SPRYFOX and Solomon Page and Warburg Pincus. The partnership between Fetch Pet Insurance and Broadway Cares was initiated by The Erlick Group,
More news about: Fetch Pet Insurance
Oct 22, 2025, 20:00 ET Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC
targeting advanced solid tumors, as well as in combination trials with PD-1 inhibitors for melanoma, CRC, NEN and HCC. Final data from the study of HBM4003 in combination with toripalimab for advanced HCC were published in Clinical Cancer Research in August 2025.
More news about: Harbour BioMed
Oct 18, 2025, 01:00 ET SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
SCG142, SCG is also advancing SCG101, a hepatitis B virus (HBV)-specific TCR T cell therapy for the treatment of HBV-related hepatocellular carcinoma (HCC). – END – About Human Papillomavirus and
More news about: SCG Cell Therapy Pte Ltd
Oct 18, 2025, 01:00 ET SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
SCG142, SCG is also advancing SCG101, a hepatitis B virus (HBV)-specific TCR T cell therapy for the treatment of HBV-related hepatocellular carcinoma (HCC). – END – About Human Papillomavirus and
More news about: SCG Cell Therapy Pte Ltd
Oct 15, 2025, 08:00 ET Reveleer Launches Industry's First All-in-One RADV Audit SaaS Solution for Medicare Advantage Compliance
AI engine, which supports dynamic validation, confidence scoring, and multi-level QA. Built-in adaptability for evolving HCC models and regulatory frameworks to maintain audit readiness. The platform also includes a provider attestation
More news about: Reveleer
Oct 14, 2025, 23:00 ET HistoIndex to debut FibroSIGHT™ Plus and showcase latest scientific findings at AASLD The Liver Meeting® 2025
detecting nuanced treatment effects in advanced MASH fibrosis and cirrhosis to continuing to expand into AATD, inflammation, vascular assessment, and MASH-HCC models, these studies highlight the wide clinical applications of our technology."
More news about: Histoindex Pte. Ltd.
Oct 14, 2025, 08:16 ET Oracle AI Database 26ai Powers the AI for Data Revolution
the low latency of memory, the high IOPS of flash, and the capacity of disk, while also reducing storage footprint using hybrid columnar compression (HCC). Finally, Exadata Database Service on Exascale Infrastructure supports Oracle Database 19c in OCI, Azure, and Google Cloud, enabling a much broader
More news about: Oracle
Oct 14, 2025, 02:19 ET Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting
(TKs), including TAM (TYRO3, AXL, and c-MER), are critical in creating environment conducive to tumor development in several cancers such as HNSCC, CRC, HCC, and RCC. GNTbm-TKI is a novel multi-targeted TKI, showing induction of immune activation in the tumor microenvironment (TME), that indicates the potential
More news about: Great Novel Therapeutics Biotech & Medicals Corporation
Oct 13, 2025, 09:24 ET Milu Health and Tokio Marine HCC - A&H Group Partner to Provide Self-Funded Plans with Opportunity to Positively Impact Members' Healthcare Experience in Real Time
Marine HCC - A&H GroupTokio Marine HCC – A&H Group is the marketing name used to describe the medical stop loss, organ transplant and group gap medical-related insurance operations of Tokio Marine HCC through its wholly owned subsidiary HCC Life Insurance Company (HCC Life). HCC Life
More news about: Milu Health
Oct 13, 2025, 06:20 ET Karmanos Shines a Green Light on Liver Cancer in October: Know the Risks, Know the Signs
growth of tumor cells in the liver without affecting normal cells. It is currently FDA approved for adult patients with advanced hepatocellular carcinoma (HCC – the most common form of liver cancer) who have failed first- and second-line therapies.
More news about: Karmanos Cancer Institute
Oct 07, 2025, 08:41 ET RAAPID Earns Microsoft Healthcare AI Certification, Strengthening Enterprise-Grade Risk Adjustment Solutions
value-based care. RAAPID's solutions, available through Azure Marketplace, deliver defensible accuracy with transparent, explainable AI that links every HCC to evidence-based clinical documentation. "This Microsoft certification recognizes our commitment to delivering secure, trusted,
More news about: RAAPID INC
Oct 02, 2025, 08:08 ET Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775
patients with HCC and severe renal impairment. LENVIMA has not been studied in patients with end-stage renal disease. No dose adjustment is recommended for patients with HCC and mild hepatic impairment (Child-Pugh A). There is no recommended dose for patients with HCC with moderate
More news about: Eisai Inc.
Oct 01, 2025, 08:02 ET October is National Liver Awareness and Liver Cancer Month, Do You Know Your Liver Health?
conditions affecting veterans, including metabolic dysfunction-associated steatotic liver disease (MASLD), cirrhosis, and hepatocellular carcinoma (HCC). October 22 at 7 to 8PM ET -
More news about: American Liver Foundation
Sep 28, 2025, 23:48 ET 2025 Trendsetting Products (Autumn) Global Launch Successfully Held in Guangzhou
GUANGZHOU, China, Sept. 28, 2025 /PRNewswire/ -- On September 23, the 2025 China Catering Brand Festival (34th HCC Catering Industry Expo), guided by the Guangzhou Municipal Bureau of Commerce and co-hosted by the World Association of Chinese Cuisine and HongCan,
More news about: Hongcan Network
Sep 24, 2025, 08:37 ET Microsoft Healthcare Executive Kim Swafford Joins RAAPID Advisory Board
payers, providers, and supporting organizations. The company's HITRUST-certified platform uses Neuro-Symbolic AI to identify chronic conditions, determine HCC codes, and provide explainable documentation for complete audit defense. Backed by M12 (Microsoft's venture fund), RAAPID serves organizations participating
More news about: RAAPID Inc
Sep 19, 2025, 10:01 ET Liver Cancer Therapeutics Market Size Surpasses USD 13.16 Billion by 2032, Increasing at a CAGR of 16.5% from 2025 to 2033
kinase inhibitors and VEGF-targeted therapies, offering durable survival outcomes for a subset of patients and reshaping the standard of care in advanced HCC. Another key advancement is the expansion of targeted oral therapies, which have improved safety and efficacy profiles. Drugs such as lenvatinib
More news about: DataM Intelligence 4 Market Research LLP
Sep 19, 2025, 09:18 ET Precision Biologics to Unveil In Vitro and In Vivo Efficacy of New ADC against human ovarian cancer at AACR Special Conference
vitro efficacy: The in vitro cytotoxicity of PB-vc-MMAE-5 was tested in four human cancer cell lines: triple-negative breast cancer (HCC1937, MDA-MB-231), ER+/PR+/HER2+ breast cancer (BT474), and ovarian cancer (OV-90). Cells were treated with varying ADC
More news about: Precision Biologics
Sep 15, 2025, 00:11 ET Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma
multinodular HCC. Data presented at the 2023 ESMO Congress revealed that the combination of cadonilimab and lenvatinib as first-line treatment for advanced HCC shows superior antitumor activity. Akeso's exploration of combination therapies with cadonilimab in the treatment of HCC offers a broad
More news about: Akeso, Inc.
Sep 14, 2025, 20:00 ET Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
candidate, which previously received both Fast Track and Orphan Drug Designations for the treatment of hepatitis B virus-related hepatocellular carcinoma (HBV-HCC).
More news about: Lion TCR
Sep 12, 2025, 00:35 ET Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig
biliary tract cancer (BTC), ovarian cancer (OC), non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC), and malignant melanoma. Encouraging clinical activity has already been observed in SCLC,
More news about: Leads Biolabs
Sep 10, 2025, 09:00 ET CareTrak® Certified by Veradigm® Connect to Deliver Real-Time, Actionable Insights at the Point of Care
administrative burdens, CareTrak® equips clinicians with real-time, intelligent insights directly at the point of care. By surfacing relevant HCC coding opportunities and quality gaps across all alternative payment models (APMs), the platform supports smarter, faster clinical decisions, driving
More news about: Persivia